{"classes":[{"categories":[{"measurements":[{"comment":"No participants in this age group.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants in this age group.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants in this age group.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG003","lowerLimit":"0.9","upperLimit":"0.9","value":"0.9"}]}],"title":"Infants and Toddlers (age<2yr; n=0; n=0; n=0; n=1)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"4.5","value":"2.0"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"6.0","value":"2.0"},{"groupId":"OG002","lowerLimit":"1.0","upperLimit":"4.1","value":"2.1"},{"groupId":"OG003","lowerLimit":"1.0","upperLimit":"2.2","value":"2.0"}]}],"title":"Children (age>=2 & <12yr; n=10; n=16; n=7; n=7)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"4.0","value":"2.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"4.0","value":"2.0"},{"groupId":"OG002","lowerLimit":"1.0","upperLimit":"8.1","value":"2.0"},{"groupId":"OG003","lowerLimit":"2.0","upperLimit":"2.1","value":"2.1"}]}],"title":"Adolescents (age>=12 & <18yr ; n=8; n=8; n=9; n=2)"},{"categories":[{"measurements":[{"comment":"No participants in this age group.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"0.9","value":"0.9"},{"comment":"No participants in this age group.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"No participants in this age group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Above 18 years (n=0; n=1; n=0; n=0)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"4.5","value":"2.0"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"6.0","value":"2.0"},{"groupId":"OG002","lowerLimit":"1.0","upperLimit":"8.1","value":"2.0"},{"groupId":"OG003","lowerLimit":"0.9","upperLimit":"2.2","value":"2.0"}]}],"title":"Total"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"10"}],"units":"Participants"}],"description":"PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.","dispersionType":"Full Range","groups":[{"description":"Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Dasatinib 60 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Dasatinib 80 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 100 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG002","title":"Dasatinib 100 mg/m^2"},{"description":"Tablets, Oral; If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Dasatinib 120 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG003","title":"Dasatinib 120 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"All treated participants with plasma samples available. n=number of PK parameters included. Each participant could have more than 1 plasma profiles sampled, depending on the number of times the dose of dasatinib was escalated.","reportingStatus":"POSTED","timeFrame":"During Week 1 of Course 1, and any course in which dose escalation was performed (at pre-dose, and at 0.5, 1, 2, 4, 6, 8 and 24 hours).","title":"Dasatinib Metabolite (BMS-582691) Plasma Pharmacokinetic (PK) Parameter: Time to Achieve the Observed Maximum Plasma Concentration (Tmax) By Dose Level and Age Group","type":"SECONDARY","unitOfMeasure":"hour"}